SCHEMBL29909466

SCHEMBL29909466

CN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1)c1nc2nnc(F)n2c2cc(N)ccc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.33
ACP1 P24666 1/20 0.33
BCR P11274 1/20 0.33
F9 P00740 1/20 0.33
SCN5A Q14524 3/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31
TUBB2A Q13885 1/20 0.31
TUBB8 Q3ZCM7 1/20 0.31
TUBA3E Q6PEY2 1/20 0.31
TUBA1A Q71U36 1/20 0.31
TUBA1C Q9BQE3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909725 0.89 ABCG2 (0.33) ABCG2DHODH
SCHEMBL30960997 0.83 SCN5A (0.34) ABL1ACP1SCN5APIM1PIM2
SCHEMBL29909748 0.82 SCN9A (0.40) ABCG2DHODHLIPE
SCHEMBL30979049 0.82 ABCG2 (0.43) ABCG2DHODH
SCHEMBL30979132 0.81 EGFR (0.43) ABCG2
SCHEMBL29909452 0.77 DHODH (0.38) ABL1ACP1SCN5AABCG2PIM1
SCHEMBL23601359 0.76 ABL1 (0.34) ABL1ACP1SCN5AABCG2PIM1
SCHEMBL23576892 0.75 SCN5A (0.35) ABL1ACP1SCN5AABCG2PIM1
SCHEMBL23576965 0.75 TP53 (0.37) TUBB3BACE1
SCHEMBL29909323 0.75 TP53 (0.37) TUBB3BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK ABL1 792/4885ACP1 475/4885BCR 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.